The new drug represents the fruit of 8 years of product development and more than 11 proprietary studies performed by Ceva R&D teams.
Marie Boutot, development project leader said: "Isemid is an original drug developed by Ceva, and was the subject of full pivotal efficacy and safety studies."
Ceva says the new drug has been recognised by the European Medicines Agency as a "2018 Innovation, advancing animal health".
Isemid is presented as pork-flavoured, scored tablets in three strengths: 1, 2 and 4 mg. They can be administered orally once daily, with or without food. The company's research showed a 98% owner compliance (compared to 92% for furosemide, p<0.05) and 80% voluntary acceptance.
Emilie Guillot, DVM, Ceva Technical Manager for Cardiology said: "With Isemid, we seek to help veterinarians in their goal to improve survival of dogs with heart failure.
"But above all, thanks to its potent action and long half-life which allow once-daily dosing, we hope to ease owner compliance."
Scientific communications with data on Isemid were presented at the American College of Veterinary Internal Medicine forum in Phoenix in June and will be held at the European College of Veterinary Internal Medicine congress in Milan in September.
Whilst you're here, take a moment to see our latest job opportunities for vets.
Veterinary Surgeon Jobs in England | Scotland | Wales | Ireland | Worldwide and
Veterinary Locums |
Follow VS Jobs on Facebook | Linkedin | Twitter | Contact
Click here to learn more about display and email advertising on VetSurgeon.org
Veterinary Forums | Veterinary News | Veterinary CPD | Veterinary Galleries
Veterinary Anaesthesia | Veterinary Cardiology | Veterinary Dentistry | Veterinary Dermatology | Diagnostic Imaging | Veterinary Medicine | Veterinary Neurology | Veterinary Oncology | Veterinary Surgery